Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

Asian equities were mostly higher overnight as Vietnam and Indonesia outperformed while Japan and India underperformed. Hong ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

The deal comes as GSK, led by chief exec Emma Walmsley (pictured) focuses on growing its pipeline to offset declining ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...

Hengrui Pharma enters agreement and with GSK to develop up to 12 innovative medicines across respiratory, immunology & inflammation & oncology: Jiangsu, China Tuesday, July 29, 20 ...

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.